ArticleJournal of internal medicine2020
Tumour biomarkers: association with heart failure outcomes.
Article in Journal of internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05704569 (Prediction of Primary Cardiovascular Events Using a Multimarker Approach), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prediction of Primary Cardiovascular Events Using a Multimarker Approach (Prospective Clinical Study)
Who cites it
28 citing papers in PubMed, 42 citations in OpenAlex.
- Preoperative brain natriuretic peptide levels are associated with postoperative all-cause mortality in patients with lung cancer.Surgery today · 2026Observational
- Diagnostics in cardio-oncology: a focus on anthracyclines.Heart failure reviews · 2026Review
- CA125 as a Potential Biomarker in Non-Malignant Serous Effusions: Diagnostic and Prognostic Considerations.Journal of clinical medicine · 2025Review
- Combined spatial metabolomics and 4D-DIA quantitative proteomics approaches to explore the relationship between lung cancer and the heart.Scientific reports · 2025Article
- Dynamics of SERPINA3 in response to anthracycline treatment and cardiovascular dysfunction.Cardio-oncology (London, England) · 2025Article
- Mendelian randomization and multiomics comprehensively reveal the causal relationship and potential mechanism between atrial fibrillation and gastric cancer.Frontiers in genetics · 2025Article
- Association between tumor markers elevation and poor functional outcomes after acute ischemic stroke: a longitudinal stroke center-based study.Annals of medicine · 2024Article
- MUC16: clinical targets with great potential.Clinical and experimental medicine · 2024Review
- A biological age model based on physical examination data to predict mortality in a Chinese population.iScience · 2024Article
- Tumor biomarkers in evaluating the severity and prognosis of idiopathic pulmonary arterial hypertension: A comprehensive analysis.Clinical and translational science · 2024Article
- Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond.Biomolecules · 2024Review
- Prospective of Pancreatic Cancer Diagnosis Using Cardiac Sensing.Journal of imaging · 2023Review
- Bioinformatics analysis of the genes associated with co-occurrence of heart failure and lung cancer.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Multifactorial Diseases of the Heart, Kidneys, Lungs, and Liver and Incident Cancer: Epidemiology and Shared Mechanisms.Cancers · 2023Review
- Association between serum carcinoembryonic antigen and cardiometabolic risks: Implication for cardiometabolic prevention.Frontiers in endocrinology · 2023Article
- High-normal serum carcinoembryonic antigen levels and increased risk of diabetic peripheral neuropathy in type 2 diabetes.Diabetology & metabolic syndrome · 2022Article
- Cardiovascular disease related circulating biomarkers and cancer incidence and mortality: is there an association?Cardiovascular research · 2022Article
- Reverse cardio-oncology: Exploring the effects of cardiovascular disease on cancer pathogenesis.Journal of molecular and cellular cardiology · 2022Review
- Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers.Frontiers in cardiovascular medicine · 2022Review
- N-Terminal Pro-Brain Natriuretic Peptide Plasma Levels Are Associated with Intermediate-Term Follow-Up Cancer in Coronary Patients.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 10 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is increasing recognition that heart failure (HF) and cancer are conditions with a number of shared characteristics.
objectivesTo explore the association between tumour biomarkers and HF outcomes.
methodsIn 2,079 patients of BIOSTAT-CHF cohort, we measured six established tumour biomarkers: CA125, CA15-3, CA19-9, CEA, CYFRA 21-1 and AFP.
resultsDuring a median follow-up of 21 months, 555 (27%) patients reached the primary end-point of all-cause mortality. CA125, CYFRA 21-1, CEA and CA19-9 levels were positively correlated with NT-proBNP quartiles (all P < 0.001, P for trend < 0.001) and were, respectively, associated with a hazard ratio of 1.17 (95% CI 1.12-1.23; P < 0.0001), 1.45 (95% CI 1.30-1.61; P < 0.0001), 1.19 (95% CI 1.09-1.30; P = 0.006) and 1.10 (95% CI 1.05-1.16; P < 0.001) for all-cause mortality after correction for BIOSTAT risk model (age, BUN, NT-proBNP, haemoglobin and beta blocker). All tumour biomarkers (except AFP) had significant associations with secondary end-points (composite of all-cause mortality and HF hospitalization, HF hospitalization, cardiovascular (CV) mortality and non-CV mortality). ROC curves showed the AUC of CYFRA 21-1 (0.64) had a noninferior AUC compared with NT-proBNP (0.68) for all-cause mortality (P = 0.08). A combination of CYFRA 21-1 and NT-proBNP (AUC = 0.71) improved the predictive value of the model for all-cause mortality (P = 0.0002 compared with NT-proBNP).
conclusionsSeveral established tumour biomarkers showed independent associations with indices of severity of HF and independent prognostic value for HF outcomes. This demonstrates that pathophysiological pathways sensed by these tumour biomarkers are also dysregulated in HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.